Today, October 5, the sky shines in the meaningful colors of the #MeningitisFlag, symbolizing hope and support on #WorldMeningitisDay. Meningitis continues to affect over 2.5 million people globally each year, highlighting the urgent need for awareness and action. Let’s unite in the fight to #DefeatMeningitis, 🔃share🔃 this post to help light the road ahead 💛💜💙 Meningitis Research Foundation
About us
We are Sanofi, an innovative global healthcare company. We chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms
- Website
-
http://www.sanofi.com
External link for Sanofi
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Paris, France
- Type
- Public Company
- Specialties
- vaccines, rare diseases, rare blood disorders, neurology, immunology, oncology, diabetes, cardiovascular diseases, and consumer healthcare
Locations
Employees at Sanofi
Updates
-
Empathy and inclusion are paramount when it comes to healthcare. That’s why we created our Cultural Sensitivity campaign to ensure diverse, equitable, and inclusive treatment environments for patients. These powerful testimonials highlight the harm medical bias can have and the need for culturally sensitive healthcare. Click below to learn more about this initiative: http://spkl.io/6048fKRfC #WeNeverSettle #IgnitingPotential #DEI #AMillionConversations
-
🔬 Discover the potential of #MonoclonalAntibody (mAb) technology and how it reflects our ambition in #Immunoscience at Sanofi. Innovative developments in mAb technology are paving the way for targeted treatments of chronic inflammatory diseases. This approach is also showing promise as a preventive tool against certain infectious diseases, such as bronchiolitis caused by Respiratory Syncytial Virus #RSV 🦠 Immunoscience holds promise to redefine R&D as we know it ✨To be continued…
-
Today, the U.S. FDA has approved our medicine as an add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. This marks the first-ever biologic approved for this progressive respiratory disease. We are proud to take the first step in transforming the treatment paradigm for COPD. Learn more: http://spkl.io/6045fKPft CC: Regeneron
-
China’s National Medical Products Administration has approved our treatment for uncontrolled chronic obstructive pulmonary disease (#COPD) characterized by raised blood eosinophils. With this approval, we hope to improve outcomes for people living with this progressive respiratory disease in China. Learn more: http://spkl.io/6042fKzLK Regeneron
-
Climate change isn’t just an environmental issue—it’s a global health crisis that affects us all. 🌍 That’s why Foundation S, our philanthropic arm, is committed to investing in building resilient healthcare systems to protect the most vulnerable populations. At the 79th UN General Assembly, the Collective MindS Climate x Health Council, a group of world-leading experts convened by Foundation S, released their latest Action Report. ➡️ This report outlines clear steps for world leaders to strengthen healthcare resilience and ensure fast, flexible funding for local health adaptation. Here’s why ensuring flexible funding reaches communities in need is crucial to addressing the health impacts of #ClimateChange 👉 http://spkl.io/6040fJITO #UNGA #ClimateFinance #GlobalGoals
-
Jane is part of our #Manufacturing & #Supply teams, and she loves being the bridge between R&D and patients, turning innovative ideas into reality for them. ✨ For Jane, passion drives her work, and she believes that diversity brings fresh perspectives and helps solve problems more effectively. Learn more: http://spkl.io/6042fJibO
-
Deep physics. Generative #AI. Big words, with even bigger potential. How can combining them accelerate drug discovery? Matt Truppo sat down with Maximilien Levesque, CEO of AQEMIA, to talk about how we are ramping up our partnership to harness AI to help translate biomedical research into new therapies. 🎥 Check out the full video to learn more about our collaboration 👉 http://spkl.io/6045fJw0T #TransformingCare #CollaborativeWorking
Sanofi x AQEMIA
-
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended the approval of our eosinophilic esophagitis (#EoE) medicine for children 1-11 years old. If approved, this would be the first and only medicine in the EU indicated for children in this age group with this chronic, progressive disease. Learn more about the news: http://spkl.io/6045fyd2B Regeneron
-
New, ground-breaking phase 3 results for our investigational #MultipleSclerosis treatment that were presented at #ECTRIMS2024. These results demonstrate an important step towards helping reduce disability accumulation in people living with #MS. Read our press release: https://lnkd.in/eJse86aa